ArticleThe Clinical biochemist. Reviews2009
Advances in biochemical screening for phaeochromocytoma using biogenic amines.
Article in The Clinical biochemist. Reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Saliva as a non-invasive matrix for assessing xenobiotic metabolites and metabolomes: implications for maternal health and preeclampsia.International journal of oral science · 2025Article
- Synthesis and Characterization of GO/ZIF-67 Nanocomposite: Investigation of Catalytic Activity for the Determination of Epinine in the Presence of Dobutamine.Micromachines · 2022Article
- Rapid Preparation of a Large Sulfated Metabolite Library for Structure Validation in Human Samples.Metabolites · 2020Article
- Label-free silver triangular nanoplates for spectrophotometric determination of catecholamines and their metabolites.Mikrochimica acta · 2020Article
- Comprehensive, robust, and sensitive UPLC-MS/MS analysis of free biogenic monoamines and their metabolites in urine.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2018Article
- Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.Hypertension (Dallas, Tex. : 1979) · 2015Article
- Catecholamines, steroids and immune alterations in ischemic stroke and other acute diseases.Aging and disease · 2014Review
- Article
- Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.The Clinical biochemist. Reviews · 2013Review
- The role of urinary fractionated metanephrines in the diagnosis of phaeochromocytoma.The Indian journal of medical research · 2013Article
- Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma.Annals of clinical biochemistry · 2013Article
- Malignant catatonia mimicking pheochromocytoma.Case reports in endocrinology · 2013Article
- Screening for pheochromocytomas and paragangliomas.Current hypertension reports · 2012Review
- Clinical experience with pheochromocytoma in a single centre over 16 years.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biochemical testing for phaeochromocytoma is performed in diagnostic laboratories using a variety of tests with plasma, serum or 24-hour urine collections. These tests include catecholamines and their methylated metabolites - the metanephrines, either individually or in combination with their sulfated metabolites. High-performance liquid chromatography (HPLC) continues to be the dominant analytical method for biogenic amine quantitation. Chromatographic techniques are changing, with improvements in sample preparation procedures, column technology and more specific analyte detection using tandem mass spectrometry. Enrolments in quality assurance programs indicate that there are still many more laboratories in Australasia analysing urinary catecholamines than metanephrines. Nevertheless, clinical evidence and expert opinion favour metanephrines as the analytes with highest sensitivity for the detection of phaeochromocytoma. Practical issues such as better chemical stability and easier specimen collection also favour metanephrines over catecholamines. For these reasons, it is likely that laboratories increasingly will replace urine catecholamine testing with either plasma or urine metanephrines. However in interpreting positive results, the need remains to consider issues such as pre-test probability and use of potentially interfering medications.
Identifiers
19224007PMC2643090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.